-- Generated TPOXX Product Revenues of $88 Million in 2025
-- Received $13 Million International Procurement Order for Oral TPOXX in
January 2026
-- Corporate Update Conference Call Today at 4:30 PM ET
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. $(SIGA)$ (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today reported financial results for the three and twelve months ended December 31, 2025.
"In 2025, we continued to advance SIGA's key long-term priorities, including securing $27 million in additional U.S. Government funding to support development activities, while generating $88 million in product revenues and $24 million in pre-tax operating income," stated Diem Nguyen, Chief Executive Officer. "In 2026, we are focused on building on our long-standing track record as a successful partner to the U.S. Government and international governments to secure new procurement contracts and orders that will serve as the foundation of our revenues in the years ahead. Accordingly, in January, we started the year strong and received a $13 million procurement order from a customer in the Asia Pacific region for oral TPOXX."
Summary Financial Results
($ in millions, except Three Months Ended Year Ended
per share amounts) December 31 December 31
-------------------- --------------
2025 2024 2025 2024
------- ------
Product sales(1) $2.2 $79.8 $88.0 $133.3
Total revenues(2) $3.8 $81.4 $94.6 $138.7
Operating (loss)/income(3) (4) ($9.5) $57.1 $23.7 $70.0
(Loss)/income before income
taxes(3) ($7.9) $58.6 $30.4 $76.1
Net (loss)/income ($5.4) $45.7 $23.3 $59.2
Diluted (loss)/income per share ($0.08) $0.63 $0.32 $0.82
---------------------------------- ----------- ------- ------ ------
(1) Includes supportive services related to product sales.
(2) Includes research and development revenues.
(3) Operating (loss)/income excludes, and (Loss)/Income before income taxes includes, other income. Both line items exclude the impact of income taxes.
(4) Differences in operating income margin between periods reflect different product mixes in those periods.
Key Activities
-- In January 2026, the Company received an order from a country in the Asia
Pacific region for $13 million of oral TPOXX$(R)$ treatment courses. The
procurement order is part of a recently signed multi-year contract that
includes options for the potential purchase of additional courses.
Courses under the $13 million procurement order are expected to be
delivered in 2026.
-- During 2025, the Company generated $53 million of oral TPOXX revenues and
$26 million of IV TPOXX revenues in connection with deliveries to the
U.S. Strategic National Stockpile. Additionally, the Company delivered $6
million of oral TPOXX to a repeating international customer.
-- In July 2025, based on the results of recently completed mpox clinical
trials, the European Medicine Agency's Committee for Medicinal Products
for Human Use $(CHMP)$ initiated a referral procedure for tecovirimat to
determine whether the benefit-risk balance of the product remains
positive for each of its approved indications. When it meets in March
2026, SIGA expects the CHMP will confirm the positive benefit-risk
balance of tecovirimat as a treatment for smallpox, cowpox, and vaccinia
complications, and maintain those indications in the product label.
Regarding mpox, based on the results of the mpox clinical trials, SIGA
expects the CHMP will recommend withdrawal of the mpox indication.
-- In June 2025, the Company's Biomedical Advanced Research and Development
Authority (BARDA) 19C contract (with the U.S. Government) was modified to
add $13 million of funding to the Company's TPOXX pediatric development
program. In combination with the $14 million of funding added in April
2025 to support manufacturing activities, $27 million of development
funding was added to the BARDA 19C contract during the second quarter.
-- In March 2025, the Company received a procurement order for $26 million
of IV TPOXX from the U.S. Government under the 19C BARDA contract.
Conference Call and Webcast
SIGA will host a conference call and webcast to provide a business update today, Tuesday, March 10, 2026, at 4:30 P.M. ET.
Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A live webcast of the call will also be available on the Company's website at www.siga.com in the Investor Relations section of the website, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time.
A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1122478. The archived webcast will be available in the Investor Relations section of the Company's website.
ABOUT SIGA
SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. For more information about SIGA, visit www.siga.com.
FORWARD-LOOKING STATEMENTS
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements relating to SIGA's future business development and plans. Forward-looking statements include statements regarding our future financial position, business strategy, budgets, projected costs, plans and objectives of management for future operations, our expectations regarding the results of the referral procedure for tecovirimat initiated by CHMP, and statements relating to the progress of SIGA's development programs and timelines for bringing products to market, and delivering products to domestic and international customers under procurement contracts, such as the 19C BARDA Contract (the "BARDA Contract"), with the U.S. Biomedical Advanced Research and Development Authority ("BARDA"). The words "may," "continue, " "estimate," "intend," "plan," "will," "believe," "project," "expect," "seek," "anticipate," "could," "should," "target," "goal," "potential" and similar expressions may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. Such forward-looking statements are subject to various known and unknown risks and uncertainties, and SIGA cautions you that any forward-looking information provided by or on behalf of SIGA is not a guarantee of future performance. SIGA's actual results could differ materially from those anticipated by such forward-looking statements due to a number of factors, some of which are beyond SIGA's control, including, but not limited to, (i) the risk that SIGA may not complete performance under the BARDA Contract on schedule or in accordance with contractual terms, (ii) the risk that SIGA is not able to enter into new contracts to supply TPOXX(R) to the U.S. Government, (iii) the risk that the nascent international biodefense market does not develop to a degree that allows SIGA to continue to successfully market TPOXX(R) internationally, (iv) the risk that potential products, including potential alternative uses or formulations of TPOXX(R) that appear promising to SIGA or its collaborators, cannot be shown to be efficacious or safe in subsequent pre-clinical or clinical trials, (v) the risk that target timing for deliveries of product to customers, and the recognition of related revenues, are delayed or adversely impacted by the actions, or inaction, of contract manufacturing organizations, or other vendors, within the supply chain, or due to coordination activities between the customer and supply chain vendors, (vi) the risk that SIGA or its collaborators will not obtain or maintain appropriate or necessary governmental approvals to market these or other potential products or uses, (vii) the risk that SIGA may not be able to secure or enforce sufficient legal rights in its products, including intellectual property protection, (viii) the risk that any challenge to SIGA's patent and other property rights, if adversely determined, could affect SIGA's business and, even if determined favorably, could be costly, (ix) the risk that regulatory requirements applicable to SIGA's products may result in the need for further or additional testing or documentation that will delay or prevent SIGA from seeking, obtaining or maintaining needed approvals to market these products, (x) the risk that the volatile and competitive nature of the biotechnology industry may hamper SIGA's efforts to develop or market its products, (xi) the risk that changes in domestic or foreign economic and market conditions may affect SIGA's ability to advance its research or may affect its products adversely, (xii) the effect of federal, state, and foreign regulation, including drug regulation and international trade regulation, on SIGA's businesses, (xiii) the impacts of significant recent shifts in trade policies, including the imposition of tariffs, retaliatory tariff measures, and subsequent modifications or suspensions
thereof, and market reactions to such policies and resulting trade disputes, (xiv) the risk of disruptions to SIGA's supply chain for the manufacture of TPOXX(R) , causing delays in SIGA's research and development activities, causing delays or the re-allocation of funding in connection with SIGA's government contracts, or diverting the attention of government staff overseeing SIGA's government contracts, (xv) risks associated with actions or uncertainties surrounding the debt ceiling, or the changes in the U.S. administration, and (xvi) the risk that the U.S. or foreign governments' responses (including inaction) to national or global economic conditions or infectious diseases, are ineffective and may adversely affect SIGA's business, as well as the risks and uncertainties included in Item 1A "Risk Factors" of our Annual Report on Form 10-K for the year ended December 31, 2025 and SIGA's subsequent filings with the Securities and Exchange Commission. SIGA urges investors and security holders to read those documents free of charge at the SEC's website at http://www.sec.gov. All such forward-looking statements are current only as of the date on which such statements were made. SIGA does not undertake any obligation to update publicly any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
Contacts:
Investors Media
Suzanne Harnett Holly Stevens, CG Life
sharnett@siga.com hstevens@cglife.com
SIGA TECHNOLOGIES, INC.
CONSOLIDATED BALANCE SHEETS
As of
December 31, 2025 December 31, 2024
------------------- -------------------
ASSETS
Current assets
Cash and cash
equivalents $ 154,966,414 $ 155,400,262
Accounts receivable 3,263,736 21,166,129
Inventory 49,054,873 49,563,880
Prepaid expenses and
other current assets 5,571,841 4,914,613
--------------- ---------------
Total current assets 212,856,864 231,044,884
Property, plant and
equipment, net 1,090,824 1,298,423
Deferred tax asset, net 4,428,519 10,854,702
Goodwill 898,334 898,334
Other assets 192,893 240,683
--------------- ---------------
Total assets $ 219,467,434 $ 244,337,026
=============== ===============
LIABILITIES AND
STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable $ 824,522 $ 1,340,337
Accrued expenses and
other current
liabilities 6,520,057 5,640,110
Deferred IV TPOXX(R)
revenue 10,240,000 10,330,800
Income tax payable 408,000 8,020,366
--------------- ---------------
Total current
liabilities 17,992,579 25,331,613
Other liabilities 2,653,283 3,200,650
--------------- ---------------
Total liabilities 20,645,862 28,532,263
Stockholders' equity
Common stock ($.0001
par value, 600,000,000
shares authorized,
71,611,302 and
71,404,669 issued and
outstanding at
December 31, 2025 and
December 31, 2024,
respectively) 7,161 7,140
Additional paid-in
capital 241,885,214 238,635,635
Accumulated deficit (43,070,803) (22,838,012)
--------------- ---------------
Total stockholders'
equity 198,821,572 215,804,763
--------------- ---------------
Total liabilities
and stockholders'
equity $ 219,467,434 $ 244,337,026
=============== ===============
SIGA TECHNOLOGIES, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
INCOME
For the Years Ended December 31
2025 2024 2023
----------- ------------ ------------
Revenues
Product sales and
supportive
services $88,048,145 $133,330,181 $130,668,209
Research and
development 6,526,757 5,389,169 9,249,011
---------- ----------- -----------
Total revenues 94,574,902 138,719,350 139,917,220
Operating expenses
Cost of sales and
supportive
services 29,703,893 31,289,229 17,825,090
Selling, general
and
administrative 21,212,694 25,136,050 22,043,023
Research and
development 19,956,159 12,310,797 16,427,942
---------- ----------- -----------
Total operating
expenses 70,872,746 68,736,076 56,296,055
---------- ----------- -----------
Operating
income 23,702,156 69,983,274 83,621,165
Other income, net 6,679,864 6,087,116 4,155,508
---------- ----------- -----------
Income before
income taxes 30,382,020 76,070,390 87,776,673
Provision for income
taxes (7,102,877) (16,856,174) (19,707,847)
---------- ----------- -----------
Net and
comprehensive
income $23,279,143 $ 59,214,216 $ 68,068,826
========== =========== ===========
Basic earnings per
share $ 0.33 $ 0.83 $ 0.95
========== =========== ===========
Diluted earnings
per share $ 0.32 $ 0.82 $ 0.95
========== =========== ===========
Weighted average
shares
outstanding:
basic 71,528,043 71,253,172 71,362,209
========== =========== ===========
Weighted average
shares
outstanding:
diluted 71,867,627 71,905,712 71,679,270
========== =========== ===========
(END) Dow Jones Newswires
March 10, 2026 16:01 ET (20:01 GMT)
Comments